Resources Contact Us Home
Browse by: INVENTOR PATENT HOLDER PATENT NUMBER DATE
 
 
Isoprenylic acid amide derivatives
4555365 Isoprenylic acid amide derivatives
Patent Drawings:

Inventor: Tahara, et al.
Date Issued: November 26, 1985
Application: 06/581,345
Filed: February 17, 1984
Inventors: Koyama; Hiroyasu (Ageo, JP)
Suzuki; Yoshikuni (Ohmiya, JP)
Tahara; Yoshiyuki (Tsurugashima, JP)
Takahashi; Toshihiro (Kawagoe, JP)
Yasuda; Masatoshi (Kitakyushu, JP)
Assignee:
Primary Examiner: Sutto; Anton H.
Assistant Examiner: Flaherty; Elizabeth A.
Attorney Or Agent: Abelman, Frayne Rezac & Schwab
U.S. Class: 514/627; 554/35
Field Of Search: 260/404
International Class:
U.S Patent Documents: 4456603; 4500463
Foreign Patent Documents: 0087136
Other References:









Abstract: Compounds of the formula R.sub.1 --CO--NH.sub.2 wherein R.sub.1 is ##STR1## are described. The compounds are useful in the treatment of hypertension and hyperlipidemia.
Claim: What we claim is:

1. An isoprenylic acid amide derivative represented by the general formula

wherein R.sub.1 is ##STR5##

2. An isoprenylic acid amide derivative according to claim 1 which is 3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetraco ntadecaenic acid amide.

3. An isoprenylic acid amide derivative according to claim 1 which is 3,7,11,15,19,23,27,31,35,39-decamethyl-6,10,14,18,22,26,30,34,38-tetracont anonaenic acid amide.

4. An isoprenylic acid amide derivative according to claim 1 which is 5,9,13,17,21,25,29,33,37,41-decamethyl-4,8,12,16,20,24,28,32,36,40-dotetra contadecaenic acid amide.

5. A therapeutic agent for treatment of hypertension which comprises as an active ingredient an antihypertensive amount of an isoprenylic acid amide derivative represented by the general formula

wherein R.sub.1 is ##STR6## in a pharmaceutically acceptable carrier.

6. A therapeutic agent for treatment of hyperlipidemia which comprises as an active ingredient an anti-hyperlipedimic amount of an isoprenylic acid amide derivative represented by the general formula

wherein R.sub.1 is ##STR7## in a pharmaceutically acceptable carrier.
Description: This invention relates to novel isoprenylic acid amide derivatives represented by the general formula

wherein R.sub.1 is ##STR2##

The isoprenylic acid amide derivatives represented by the general formula (I) of this invention are compounds which are useful as therapeutic agents for treatment of hypertension and hyperlipidemia.

For preparation of compounds of the general formula (I) in this invention, all the techniques for formation of amide linkage in ordinary synthesis of peptides are applicable. In more detail according to this invention, the novel isoprenylic acidamide derivatives represented by the general formula

wherein R.sub.1 is ##STR3## can be manufactured by bringing ammonia to react with

(i) acids represented by the general formula R.sub.1 COOH wherein R.sub.1 is ##STR4## in the presence of condensing agent used for synthesis of peptides,

(ii) acid halides represented by the general formula R.sub.1 COX wherein R.sub.1 is the same as described above and X is a halogen atom, in the presence of a base, or

(iii) active esters of an acid represented by the general formula R.sub.1 COOR' wherein R.sub.1 is the same as described above and R' is an active ester residue used in the synthesis of peptides, or an acid azide selected from a seriesrepresented by the general formula R.sub.1 CON.sub.3 wherein R.sub.1 is the same as described above.

Describing the manufacturing process in greater detail, the reaction of ammonia and an acid is carried out for several minutes to tens of hours, preferably for 1 to 30 hours at 50.degree. to 100.degree. C., preferably at 0.degree. to25.degree. C. in an inert solvent in the presence of a condensing agent when a compound represented by the general formula R.sub.1 COOH is used. Ammonia and condensing agent are preferably used in excess of the equimolar proportion of the acid,respectively. Typical compounds used as the condensing agent include N,N-dicyclohexylcarbodiimide and ditolylcarbodiimide. The inert solvents used include halogenated lower aliphatic hydrocarbons, such as chloroform, methylene chloride andtrichloroethylene; lower aliphatic lower alkyl esters such as ethyl acetate and butyl acetate; lower aliphatic alcohols such as ethanol, isopropanol and t-butanol; lower fatty acid lower alkyl amides such as N,N-dimethylformamide; lower aliphatic ketonessuch as acetone and methylethylketone; aromatic hydrocarbons such as benzene and toluene; lower aliphatic alicyclic ethers such as tetrahydrofuran, dioxan and ether; heterocyclic compounds such as pyridine; and nitriles such as acetonitrile.

The reaction with an acid halide is carried out in the presence of a base in an inert solvent at -50.degree. to 100.degree. C., preferably at 0.degree. to 25.degree. C., for several minutes to tens of hours, preferably for 30 minutes to 3hours, when the compounds represented by the general formula R.sub.1 COX are used instead of the compounds represented by the general formula R.sub.1 COOH. Ammonia is preferably used in excess of the equimolar proportion to the acid halide. The basesused include tertiary amines such as triethylamine and dimethylaniline and heterocyclic compounds such as pyridine. The inert solvents used include ordinary organic solvents such as chloroform, methylene chloride, ethyl acetate, N,N-dimethylformamide,acetone, benzene, toluene, tetrahydrofuran, dioxan, ethyl ether, pyridine and acetonitrile.

The reaction with an active ester of acid or an acid azide in an inert solvent is carried out at -50.degree. to 70.degree. C., preferably at 0.degree. to 25.degree. C. for several minutes to tens of hours, preferably from 30 minutes to 20hours when the compounds represented by the general formula R.sub.1 COOR' and general formula R.sub.1 CON.sub.3 are used instead of the compounds represented by the general formula R.sub.1 COOH. Ammonia is preferably used in excess of the equimolarproportion to the active ester of acid and acid azide, respectively. The active ester groups of active esters of acid include p-nitrophenyl group, pentachlorophenyl group, succinimide group, phthalimide group, and so forth. All of the inert solventsmentioned above can be utilized for the reaction.

The desired isoprenoid acid amide derivatives are obtained when the reaction mixture after the end of the reaction described is condensed either with or without filtration, or the mixture is subjected to extraction with solvents such as ethylacetate, chloroform, hexane, benzene and subsequently purified by means of column chromatography with silica gel or alumina.

This invention is illustrated in further detail in the following examples.

EXAMPLE 1

3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracon tadecaenic acid amide

25 g of 3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetraco ntadecaenic acid is dissolved in 100 ml of benzene, to which 6.8 ml of 28% sodium methoxide solution is added to form sodium salt, and from which the solvent isremoved to dryness under reduced pressure. The dried residue is then dissolved in 100 ml of benzene, added with a trace amount of pyridine, and to which 6 ml of oxalyl chloride is added dropwise at 0.degree. C. with ice bath cooling and stirring. Thereaction mixture is kept at 0.degree. C. for 30 minutes, allowed to react at room temperature for 1 hour, and then condensed under reduced pressure. The residue is dissolved in dichloromethylene, and mixed dropwise for 30 minutes with a mixture, cooledbelow 5.degree. C., consisting of 50 ml of concentrated ammonia liquor, 10 ml of triethylamine and 100 ml of benzene. Stirring is continued further for 2 hours, at room temperature. The reaction mixture is subsequently left standing overnight at roomtemperature, poured into water, extracted with ethyl acetate, and washed sequentially with water, diluted hydrochloric acid, diluted alkali and water. The ethyl acetate phase is distilled to remove the solvent after desiccation with anhydrous sodiumsulfate. The residue is subjected to column chromatography using benzene/ethyl acetate mixture for elution solvent. The product was obtained as an oily substance in light yellow color (yield: 18 g). This oily substance was dissolved in 90 ml ofacetone and left overnight in a refrigerator. White crystals deposited were filtered off, dried and thus yielded 13.5 g of desired final product, acid amide derivative. Physical properties of this product are as the following:

m.p.: 46.4.degree.-49.6.degree. C.

Elemental analysis (as C.sub.50 H.sub.81 ON)

______________________________________ C (%) H (%) N (%) ______________________________________ Calculated 84.32 11.46 1.97 Found 84.15 11.51 1.95 ______________________________________

IR spectrum (cm.sup.-1): 3330, 3190, 1663, 1640, 1610.

Mass M.sup.+ : 712.

NMR spectrum (.delta., CDCl.sub.3): 5.40-4.80 (br 10H); 2.00 (br-s 36H); 1.60 (br-s 33H).

EXAMPLE 2

3,7,11,15,19,23,27,31,35,39-decamethyl-6,10,14,18,22,26,30,34,38-tetraconta nonaenic acid amide

20 g of 3,7,11,15,19,23,27,31,35,39-decamethyl-6,10,14,18,22,26,30,34,38-tetracont anonaenic acid are dissolved in 100 ml of methylene chloride. To this solution, 6.9 g of N,N-dicyclohexylcarbodiimide are added with cooling at 0.degree. C., andstirred for 1.0 hour. Ammonia gas is blown little by little into this solution during an hour. Stirring for 3.0 hours is performed at room temperature after the end of addition of ammonia. Mother liquor is condensed after filtering offN,N-dicyclohexylurea formed. The residue is subjected to silica gel column chromatography using benzene/ethyl acetate mixture for eluting solvent. The desired product was obtained as an oily substance light yellow in color (yield: 12.3 g). This oilysubstance was dissolved in 50 ml of acetone and left overnight in a refrigerator. The white crystals deposited were filtered off, dried and thus yielded 8.5 g of desired final product, acid amide derivative.

Physical properties of this product are as follows:

m.p.: 47.9.degree.-50.6.degree. C.

Elemental analysis (as C.sub.50 H.sub.83 NO)

______________________________________ C (%) H (%) N (%) ______________________________________ Calculated 84.09 11.71 1.96 Found 84.20 11.76 1.95 ______________________________________

IR spectrum (cm.sup.-1): 3350, 3190, 1650, 1620.

NMR spectrum (.delta., CDCl.sub.3): 5.4-4.8 (br 9H); 2.00 (br-s 38H); 1.60 (br-s 30H); 0.98 (d 3H).

EXAMPLE 3

5,9,13,17,21,25,29,33,37,41-decamethyl-4,8,12,16,20,24,28,32,36,40-dotetrac ontadecaenic acid amide

25 g of 5,9,13,17,21,25,29,33,37,41-decamethyl-4,8,12,16,20,24,28,32,36,40-dotetra contadecaenic acid are dissolved in 100 ml of methylene chloride. To this solution, 8.0 g of N,N-dicyclohexylcarbodiimide are added and stirred for 1 hour. 4.5 gof N-hydroxysuccinimide are added and stirred for 3 hours. N,N-dicyclohexylurea thus formed was filtered off; the mother liquor was condensed; and 27.8 g of residue was obtained. The residue was subjected to silica gel column chromatography usinghexane/benzene mixture for eluting solvent, and yielded 20.8 g of succinimide ester of 5,9,13,17,21,25,29,33,37,41-decamethyl-4,8,12,16,20,24,28,32,36,40-dotetra contadecaenic acid.

20.8 g of the succinimide ester described above is dissolved in 100 ml of tetrahydrofuran, into which ammonia gas is blown little by little during 1.0 hour. After the end of ammonia blowing, the solution was stirred at room temperature for 3hours. 21.1 g of residue was obtained after distilling off the solvent. This residue was purified by silica gel column chromatography using benzene/ethyl acetate mixture for eluting solvent and thus yielded 11.3 g of desired product which is oily andlight yellow in color. This oily substance was dissolved in 50 ml of acetone and left overnight in a refrigerator. White crystals which were deposited were filtered off, dried and thus yielded 7.8 g of desired acid amide derivative. Physicalproperties of this derivative are as the following:

m.p.: 58.6.degree.-61.8.degree. C.

Elemental analysis (as C.sub.52 H.sub.85 NO)

______________________________________ C (%) H (%) N (%) ______________________________________ Calculated 84.37 11.57 1.89 Found 84.30 11.38 1.81 ______________________________________

IR spectrum (cm.sup.-1): 3410, 3200, 1660, 1620.

NMR spectrum (.delta., CDCl.sub.3): 5.40-4.80 (br 10H); 2.00 (br-s 40H); 1.62 (br-s 33H).

Pharmacological tests on the isoprenylic acid amide derivatives according to this invention are described as follows:

(1) Antihypertensive effect on spontaneous hypertension rats (SHR)

Test procedure:

20-week-old SHR were used. Mean blood pressure was 170-180 mm Hg on average. The compound to be tested was suspended in 5% gum arabic and orally administered to SHR. Blood pressure in the descending aorta was measured directly by means of acannula which had been embedded on the day before testing. Measurements were performed before administration, and at 2, 4, 6 and 24 hours after administration to observe the changes in mean blood pressure.

Compound tested:

3,7,11,15,19,23,27,31,35,39-decamethyl-6,10,14,18,22,26,30,34,38-tetraconta nonaenic acid amide [Compound (A)]

Dose: 200 mg/kg

Result: Mean blood pressure of SHR was 176 mm Hg before administration. The value was reduced by 17 mm Hg after the administration. This hypotensive effect was observed even at 6 hours after the administration. Heart rate was not affected atall by this compound.

(2) Antihyperlipidemic effect

Test procedure:

Rats that became hyperlipidemic by being fed 1% cholesterol-contained diet for 10 previous days were used. Compound to be tested was added to make up 0.3% in cholesterol-contained diet, and 10 g of this diet were fed daily to the rats. Totalcholesterol, triglyceride and HDL in the serum and total cholesterol in the liver were determined. Antihyperlipidemic effects of the reference compound, clofibrate, were compared with those of the compound tested.

Compound tested: Compound (A)

Result: The compound tested showed biological effects in decreasing cholesterol in the serum and liver, increasing HDL, and decreasing triglyceride in the serum; and the potency was comparable to that of clofibrate.

Based on the pharmacological tests described above, the compound according to this invention is useful in showing antihypertensive effect as well as improving the lipid metabolism. It is promising as a preventive and therapeutic agent againstrenal, endocrine and essential hypertension as well as a preventive and therapeutic agent against various diseases accompanying arteriosclerosis.

Clinical dosage of the compound according to this invention is generally 200-5000 mg/day and preferably 500-4000 mg/day orally.

* * * * *
 
 
  Recently Added Patents
Image playback device and method and electronic camera with image playback function
Data processing system, data processing method, and image forming apparatus
Power or voltage oscillation damping in a power transmission system
Transferring a document
High performance data transport system and method
System and method for reliable packet data transport in a computer network
Business flow processing method and apparatus
  Randomly Featured Patents
Sled
Information management method and information management device
Torque converter having torsional damper
Secure computer communication method and system
McLeod harvesting system and method
Portable crushing plant
Apparatus for setting up and loading a tray
System and method for interactive marketing using networked devices
Light-generating wheel for an in-line skate
Device authentication system and method for determining whether a plurality of devices belong to a group